GoAI
Get started
LifeMD, Inc. logo

LifeMD, Inc.

LFMD

NASDAQHealthcareMedical - Healthcare Information Services

Open in GoAI

Previous close

$3.31

+$0.03 · +0.91%

Aug 21, 4:00 PM ET

LFMD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

53

Fair Value

Momentum

44

Neutral

Sentiment

67

Bullish

Risk resilience

23

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical device, and custom-compounded topical treatments for both male and female hair loss. RexMD serves as a men's telehealth brand, providing virtual medical treatment from licensed providers for a wide array of male-specific health needs. LifeMD Primary Care offers a personalized, subscription-based virtual primary care solution, addressing routine, urgent, and chronic health management requirements. This mobile-centric platform integrates remote consultations, medication management, diagnostic services, and imaging referrals. Cleared is a telehealth service dedicated to offering personalized therapies for allergic, asthmatic, and immunological conditions. Nava MD stands as a skincare and tele-dermatology brand catering specifically to women, facilitating virtual access to dermatologists and other specialists for medical treatment. Additionally, the company provides PDFSimpli, a cloud-based software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents online. LifeMD distributes its offerings directly to individuals, via its own e-commerce channels, and through collaborations with external partners. Originally established in 1994 as Conversion Labs, Inc., the company rebranded to LifeMD, Inc. in February 2021 and is headquartered in New York City.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Justin Schreiber
Listed since
Jan 29, 2008
Employees
350

Market position

Day range

Current $3.31

52-week range

Current $3.31

Open
$3.31
Previous close
$3.28
Volume
406.48K
0.39× average
Average volume
1.04M
Average daily volume
Market cap
160.08M USD
Beta
2.06
Market reference 1
50-day average
$4.1026
-19.32% below average
200-day average
$3.9472
-16.14% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
123.43M USD
P/E (TTM)
-6.52×
P/B (TTM)
19.86×
P/S (TTM)
0.78×
EV / EBITDA
-81.36×
Earnings yield
-4.62%
Free cash flow yield
-0.80%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
85.91%
Operating margin
-9.35%
Net margin
-10.40%
Return on equity
-30.69%
Return on assets
-10.09%
Return on invested capital
-26.02%

Financial health

Debt / equity
0.76×
Current ratio
1.25×
Altman Z-score
-1.69
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends104%42%-19%-81%Gross margin, FY2021: 80.62%Gross margin, FY2022: 84.32%Gross margin, FY2023: 87.61%Gross margin, FY2024: 88.67%Gross margin, FY2025: 79.75%Operating margin, FY2021: -58.47%Operating margin, FY2022: -36.50%Operating margin, FY2023: -9.50%Operating margin, FY2024: -7.60%Operating margin, FY2025: -3.95%Net margin, FY2021: -65.57%Net margin, FY2022: -38.25%Net margin, FY2023: -13.50%Net margin, FY2024: -8.89%Net margin, FY2025: -3.66%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 80.62%. Gross margin FY2022 84.32%. Gross margin FY2023 87.61%. Gross margin FY2024 88.67%. Gross margin FY2025 79.75%. Operating margin FY2021 -58.47%. Operating margin FY2022 -36.50%. Operating margin FY2023 -9.50%. Operating margin FY2024 -7.60%. Operating margin FY2025 -3.95%. Net margin FY2021 -65.57%. Net margin FY2022 -38.25%. Net margin FY2023 -13.50%. Net margin FY2024 -8.89%. Net margin FY2025 -3.66%.

Income trends

Revenue

194.06M USD-8.66%

Operating income

−7.67M USD+52.49%

Net income

−7.11M USD+62.36%
Income trends across reported periods239.79M USD130.45M USD21.11M USD−88.23M USDRevenue, FY2021: 92.88M USDRevenue, FY2022: 119.03M USDRevenue, FY2023: 152.55M USDRevenue, FY2024: 212.45M USDRevenue, FY2025: 194.06M USDOperating income, FY2021: −54.3M USDOperating income, FY2022: −43.45M USDOperating income, FY2023: −14.49M USDOperating income, FY2024: −16.14M USDOperating income, FY2025: −7.67M USDNet income, FY2021: −60.9M USDNet income, FY2022: −45.54M USDNet income, FY2023: −20.6M USDNet income, FY2024: −18.88M USDNet income, FY2025: −7.11M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 92.88M USD. Revenue FY2022 119.03M USD. Revenue FY2023 152.55M USD. Revenue FY2024 212.45M USD. Revenue FY2025 194.06M USD. Operating income FY2021 −54.3M USD. Operating income FY2022 −43.45M USD. Operating income FY2023 −14.49M USD. Operating income FY2024 −16.14M USD. Operating income FY2025 −7.67M USD. Net income FY2021 −60.9M USD. Net income FY2022 −45.54M USD. Net income FY2023 −20.6M USD. Net income FY2024 −18.88M USD. Net income FY2025 −7.11M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue194.06M USD212.45M USD152.55M USD119.03M USD92.88M USD
Cost of goods sold39.29M USD24.07M USD18.9M USD18.67M USD18M USD
Gross profit154.76M USD188.39M USD133.65M USD100.37M USD74.88M USD
Research and development7.35M USD9.51M USD6.06M USD2.97M USD948.16K USD
Selling, general, and administrative144.01M USD175.68M USD128.15M USD125.33M USD122.08M USD
Operating expenses162.43M USD204.53M USD148.14M USD143.81M USD129.18M USD
Interest expense1.36M USD2.18M USD2.6M USD1.28M USD3.02M USD
Depreciation and amortization7.31M USD9.49M USD6.6M USD1.09M USD355.87K USD
Operating income−7.67M USD−16.14M USD−14.49M USD−43.45M USD−54.3M USD
Net income−7.11M USD−18.88M USD−20.6M USD−45.54M USD−60.9M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-41.61%
11 comparable reports
Latest EPS result
-0.16
Estimate -0.15 · Miss by 9.81%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.220.07-0.09-0.24Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual -0.02, estimate -0.04, surprise +50.00%, Beat. Q2 2025, reported May 6, 2025: actual 0.01, estimate -0.04, surprise +125.00%, Beat. Q3 2025, reported Aug 4, 2025: actual -0.047, estimate 0.18, surprise -125.96%, Miss. Q4 2025, reported Nov 17, 2025: actual -0.1, estimate -0.06, surprise -66.67%, Miss. Q1 2026, reported Mar 9, 2026: actual -0.04, estimate -0.01, surprise -300.00%, Miss. Q2 2026, reported May 6, 2026: actual -0.2, estimate -0.14, surprise -42.86%, Miss. Q3 2026, reported Aug 5, 2026: actual -0.16, estimate -0.146, surprise -9.81%, Miss. Q4 2026, reported Nov 16, 2026: actual —, estimate -0.16, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates68.97M60.37M51.77M43.17MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual 64.25M USD, estimate 59.62M USD, surprise +7.77%, Beat. Q2 2025, reported May 6, 2025: actual 65.7M USD, estimate 65.46M USD, surprise +0.36%, Beat. Q3 2025, reported Aug 4, 2025: actual 62.22M USD, estimate 66.31M USD, surprise -6.18%, Miss. Q4 2025, reported Nov 17, 2025: actual 60.17M USD, estimate 48.57M USD, surprise +23.88%, Beat. Q1 2026, reported Mar 9, 2026: actual 46.87M USD, estimate 45.82M USD, surprise +2.28%, Beat. Q2 2026, reported May 6, 2026: actual 50.16M USD, estimate 48.84M USD, surprise +2.71%, Beat. Q3 2026, reported Aug 5, 2026: actual 47.3M USD, estimate 49.16M USD, surprise -3.78%, Miss. Q4 2026, reported Nov 16, 2026: actual —, estimate 48.77M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.67

131.72% upside
Past 12 months12-month forecastHigh $10.00Average $7.67Low $5.00

Recent analyst actions

10 institutions
Freedom Capital MarketsmaintainBuy

LFMD news

seekingalpha.com

LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript

LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

LifeMD Q2 Earnings Call Highlights

LifeMD NASDAQ: LFMD reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million as elevated customer acquisition costs and a…

Read source
zacks.com

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.06 per share a year ago.

Read source
globenewswire.com

UPDATE - LifeMD Reports Second Quarter 2026 Results

UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47. 3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA loss of…

Read source
globenewswire.com

UPDATE - LifeMD Reports Second Quarter 2026 Results

UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA loss of…

Read source
defenseworld.net

Critical Survey: Ryman Healthcare (OTCMKTS:RYHTY) vs. LifeMD (NASDAQ:LFMD)

LifeMD (NASDAQ: LFMD - Get Free Report) and Ryman Healthcare (OTCMKTS:RYHTY - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength…

Read source

Corporate actions

Corporate action history

Stock split

Effective Oct 14, 2020

1:5

LFMD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LFMD

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
4.29M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.37M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
State Street SPDR S&P Kensho New Economies Composite ETF logoState Street SPDR S&P Kensho New Economies Composite ETFKOMP
Market value
1.73M
Weight
0.06%
AUM
2.71B USD
Expense ratio
0.20%
Price / 1D
$69.24+0.92%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.66M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
932.82K
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
780.84K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
448.77K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
267.83K
Weight
0.00%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%

Continue in GoAI

Research LFMD

research.disclaimer